Cantharidin
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
以下是根據 Evidence Pack 產生的完整評估報告：
Cantharidin: From Traditional Chinese Medicine to Amenorrhea
One-Sentence Summary
Cantharidin is a naturally occurring vesicant toxin derived from blister beetles (Mylabris spp.), historically classified as 斑蝥 in traditional Chinese medicine and studied for its cytotoxic and PP2A-inhibitory properties, but currently without any approved modern indication in the United States. The TxGNN model predicts it may be effective for Amenorrhea, likely driven by ethnopharmacological associations in the knowledge graph. However, with 0 clinical trials and 0 publications directly supporting this direction, the evidence base is entirely model-driven at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No approved indication (traditional/experimental use only) |
| Predicted New Indication | Amenorrhea |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L5 |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, no approved indication or detailed mechanism of action data is available in the evidence pack. Based on known pharmacological information, cantharidin is a potent protein phosphatase 2A (PP2A) inhibitor and the active vesicant constituent of Mylabris spp. (blister beetles). It has documented cytotoxic and anti-proliferative activity, and has been explored in preclinical cancer research. In traditional Chinese medicine, 斑蝥 has historically been used as an emmenagogue — a substance intended to stimulate or restore menstruation — which provides a plausible ethnopharmacological rationale for why the TxGNN knowledge graph links cantharidin to amenorrhea.
The TxGNN score of 0.994 likely reflects this traditional-use pathway and indirect biomolecular associations encoded in the training graph rather than a direct mechanistic chain. No established modern pharmacological mechanism connects PP2A inhibition to hypothalamic–pituitary–ovarian axis regulation or endometrial cycle control. This association should therefore be regarded as highly speculative pending any primary biomedical investigation.
It is also important to note that cantharidin carries a very narrow therapeutic window and significant systemic toxicity risk (nephrotoxicity, vesication, GI toxicity), which poses substantial safety barriers to clinical translation in a chronic condition such as amenorrhea.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Cytotoxicity
Cantharidin is a potent cytotoxic natural compound (PP2A inhibitor); the following assessment is based on known compound pharmacology.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic — natural toxin (terpenoid vesicant), PP2A inhibitor class |
| Myelosuppression Risk | Please refer to primary toxicology literature; systemic myelotoxicity has been reported in poisoning cases |
| Emetogenicity Classification | Please refer to primary toxicology literature; GI toxicity (nausea, vomiting, mucosal irritation) is a known systemic effect |
| Monitoring Items | Renal function (nephrotoxicity is a primary concern), hepatic function, CBC, urinalysis |
| Handling Protection | Must follow cytotoxic/vesicant handling regulations; cantharidin causes severe skin and mucous membrane blistering on contact |
Safety Considerations
No US package insert data is available, as cantharidin has no approved indications and is not marketed in the United States. Cantharidin is a scheduled toxic substance with a well-documented narrow therapeutic window and vesicant properties. Please consult primary toxicology resources and institutional safety protocols before any handling or research use.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN high score (99.42%) for amenorrhea most likely reflects traditional Chinese medicine ethnopharmacological signal in the knowledge graph rather than a validated modern mechanistic link; with zero supporting clinical trials or peer-reviewed publications, this candidate sits at L5 — model prediction only — and carries a significant unresolved toxicity profile that makes clinical translation premature.
To proceed, the following is needed:
- Mechanism of action clarification: establish whether PP2A inhibition has any plausible role in menstrual cycle or ovarian hormonal regulation
- Preclinical in vitro / in vivo efficacy studies specifically targeting amenorrhea models
- Dose–response and safety characterisation at sub-vesicant systemic exposures
- Formal DrugBank safety data retrieval (warnings, contraindications, DDI profile) to complete the S1 safety gate
- TFDA prescribing information review if any historical local data exists
- At minimum one Phase 1 clinical study establishing a safe dose range before any efficacy claim can be evaluated
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.